The challenge of pancreatic endoscopic ultrasound‐guided fine needle aspiration cytology

V. Wadehra

DOI: https://doi.org/10.1111/cyt.12069

2013-06-01

Cytopathology

Abstract:Cytopathology is a challenging subspecialty with a wide variety of specimens from a multitude of lesions to decipher. Endoscopic ultrasound-guided (EUS) fine needle aspiration (FNA) cytology samples from the pancreas are amongst the most challenging to interpret cytologically, have a wide diagnostic range to engage, confusing variants of classical tumours to interpret and cytological rarities to add interest. All this is well represented in this issue of Cytopathology, which deals with methods of improving specimen adequacy, the advantages and pressures of providing rapid on-site evaluation (ROSE) of cytology slides, the role of cytotechnologists and the place of cytology in the multidisciplinary and multimodal diagnosis of solid and cystic pancreatic neoplasms and lesions. Pancreatic carcinoma is the fifth leading cause of cancer deaths in the UK. Its mortality remains stubbornly high and its survival is amongst the lowest in cancers. Pancreatic ductal adenocarcinomas constitute 85–90% of all pancreatic neoplasms. The 5-year survival for these common pancreatic cancers is reported to be around 5%. Early diagnosis, when the tumour is limited to the pancreas and thus amenable to surgery, is critical to improve survival. Pancreatic cancers/lesions are sometimes resected or explored without cellular confirmation, and the great majority of unnecessary pancreatectomies in those cases are caused by chronic pancreatitis, especially autoimmune pancreatitis. An awareness of this great mimic of pancreatic cancer, the estimation of serum IgG4 in cases of chronic pancreatitis presenting with a mass-like lesion and immunocytochemistry to show IgG4 positivity when plasma cells are seen on FNA cytology are helpful. The introduction of EUS diagnosis with FNA cytology helps smaller lesions than previously possible to be located and sampled under computed tomography (CT) guidance or with endoscopic retrograde cholangiopancreatography (ERCP). In this issue of Cytopathology, the review article by Dina et al., which illustrates the main conditions likely to be encountered with pancreatic EUS FNA, explains the difficulties in diagnosis and the vital role played by multidisciplinary teams (MDTs) in pancreatic cancer diagnosis and management. An FNA cytology report categorized as suspicious for pancreaticobiliary carcinoma, in the correct clinical and radiological context, can thus be interpreted and managed as a positive case. They also advocate rapid on-site evaluation of slides by cytotechnologists/biomedical scientists (BMS) to avoid inadequate cytology.